| Title |
Pembrolizumab: First Global Approval
|
|---|---|
| Published in |
Drugs, October 2014
|
| DOI | 10.1007/s40265-014-0314-5 |
| Pubmed ID | |
| Authors |
Raewyn M. Poole |
| Abstract |
Pembrolizumab [Keytruda(®) (US)], a humanized monoclonal antibody against the programmed death receptor-1 (PD-1) protein, has been developed by Merck & Co for the treatment of cancer. Pembrolizumab has received its first global approval for the treatment of advanced, unresectable or metastatic malignant melanoma in the US, for use in patients with disease progression after prior treatment with ipilimumab and, for BRAF V600 mutation-positive patients, a BRAF inhibitor. It is the first anti-PD-1 therapy to receive regulatory approval in the US, and is currently under regulatory review in the EU. This article summarizes the milestones in the development of pembrolizumab leading to this first approval for the treatment of malignant melanoma. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Poland | 1 | 50% |
| Saudi Arabia | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 134 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ecuador | 1 | <1% |
| Germany | 1 | <1% |
| Austria | 1 | <1% |
| Unknown | 131 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 27 | 20% |
| Researcher | 19 | 14% |
| Student > Master | 15 | 11% |
| Student > Ph. D. Student | 12 | 9% |
| Student > Postgraduate | 6 | 4% |
| Other | 13 | 10% |
| Unknown | 42 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 16% |
| Biochemistry, Genetics and Molecular Biology | 19 | 14% |
| Agricultural and Biological Sciences | 16 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 5% |
| Immunology and Microbiology | 7 | 5% |
| Other | 15 | 11% |
| Unknown | 48 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 December 2023.
All research outputs
#6,575,550
of 23,269,984 outputs
Outputs from Drugs
#1,128
of 3,297 outputs
Outputs of similar age
#71,479
of 261,063 outputs
Outputs of similar age from Drugs
#15
of 36 outputs
Altmetric has tracked 23,269,984 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 3,297 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 261,063 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 36 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.